^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Lymphoma
    Drug:acimtamig (AFM13) (CD16A agonist, CD30 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

    Excerpt:
    ...mycosis fungoides (MF), or B-cell non-Hodgkin lymphoma with a pre-enrollment tumor biopsy positive for CD30 by immunohistochemistry at >= 1%....
    Trial ID:
    NCT04074746
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

    Excerpt:
    ...- Histologically confirmed CD30-positive PTCL (most subtypes allowed) or TMF per the revised World Health Organization 2016 classification (Swerdlow, 2016) by central assessment....
    Trial ID:
    REDIRECT
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    AFM13 in Relapsed/Refractory Cutaneous Lymphomas

    Excerpt:
    ...- Histologically confirmed CD30-positive lymphoma with cutaneous involvement...
    Trial ID:
    NCT03192202
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies

    Published date:
    05/13/2021
    Excerpt:
    L-12/15/18-induced memory-like NK cells from peripheral blood exhibited enhanced killing of CD30+ lymphoma targets directed by AFM13, compared to cNK cells. AFM13-NK complex cells exhibited enhanced responses to CD30+ lymphomas in vitro and in vivo.
    DOI:
    10.1158/1078-0432.CCR-21-0164